STOCK TITAN

Crinetics (NASDAQ: CRNX) director receives new RSU and stock option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Crinetics Pharmaceuticals director Nichols Weston received new equity awards. The filing shows a grant of 5,925 shares of common stock in the form of restricted stock units, bringing his direct common share holdings to 22,225. He was also granted a stock option over 9,730 shares of common stock at an exercise price of $35.87 per share, expiring on June 18, 2036. Both the restricted stock units and the option vest 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual meeting of stockholders, subject to his continued service on the board.

Positive

  • None.

Negative

  • None.
Insider Nichols Weston
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 9,730 $0.00 --
Grant/Award Common Stock 5,925 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 9,730 shares (Direct, null); Common Stock — 22,225 shares (Direct, null)
Footnotes (1)
  1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Restricted stock units granted 5,925 shares RSU grant to director on June 18, 2026
Common shares held after grant 22,225 shares Director’s direct holdings after RSU award
Stock option grant size 9,730 shares New option covering common stock
Option exercise price $35.87 per share Strike price for new stock option
Option expiration date June 18, 2036 Final expiration of granted stock option
restricted stock units financial
"involves the receipt of restricted stock units, which represent the right to receive shares"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock option financial
"The stock option shall vest and become exercisable on the earlier of"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
vest financial
"100% vesting on the earlier of (a) the first anniversary of the grant date"
A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.
annual meeting of the Issuer's stockholders financial
"the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Nichols Weston

(Last)(First)(Middle)
C/O CRINETICS PHARMACEUTICALS, INC.
6055 LUSK BOULEVARD

(Street)
SAN DIEGO CALIFORNIA 92121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Crinetics Pharmaceuticals, Inc. [ CRNX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/18/2026A5,925A$0(1)22,225D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$35.8706/18/2026A9,730 (2)06/18/2036Common Stock9,730$09,730D
Explanation of Responses:
1. The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 100% vesting on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
2. The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.
Remarks:
/s/ Tobin Schilke, as attorney-in-fact06/22/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Nichols Weston receive from Crinetics (CRNX)?

Nichols Weston received 5,925 restricted stock units and a stock option over 9,730 shares of Crinetics common stock. These awards represent compensation for his service as a director rather than open-market purchases.

What is the exercise price of Nichols Weston’s new Crinetics stock options?

The new stock option granted to Nichols Weston has an exercise price of $35.87 per share. It covers 9,730 underlying shares of Crinetics common stock and expires on June 18, 2036, if not earlier exercised or forfeited.

When do Nichols Weston’s restricted stock units and options in CRNX vest?

Both the 5,925 restricted stock units and the 9,730-share stock option vest 100% on the earlier of the first anniversary of the June 18, 2026 grant date or the next annual stockholder meeting, assuming he continues serving on the board through vesting.

How many Crinetics shares does Nichols Weston hold after this Form 4?

After the reported grant, Nichols Weston directly holds 22,225 shares of Crinetics common stock. He also holds a newly granted stock option covering 9,730 additional shares, which will be exercisable after the vesting conditions are met.

Are Nichols Weston’s new CRNX awards open-market buys or compensation grants?

The reported transactions are compensation-related grants, not open-market buys. They consist of restricted stock units and a stock option award, both granted at no cash cost to him and vesting based on continued board service.